[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"small-intestinal-bacterial-overgrowth-syndrome-sibo\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:small-intestinal-bacterial-overgrowth-syndrome-sibo":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,78,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100651939","phase-2-herbal-supplement-biocidin-remove-for-bacterial-overgrowth-in-irritable-bowel-syndrome-100651939",false,"NCT07768267","Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome","A Pilot Study of the Role of an Antimicrobial Herbal Formulation (Biocidin REMOVE) for the Management of Small Intestinal Bacterial Overgrowth (SIBO) in Patients With Irritable Bowel Syndrome (IBS)","Inclusion Criteria:\n\n* Age 18 years or older\n* Irritable bowel syndrome by Rome IV criteria with a positive lactulose breath test for small intestinal bacterial overgrowth, defined as a rise of more than 20 parts per million of hydrogen above baseline in the first 90 minutes of testing and\u002For a methane level of 10 parts per million or greater at any point during the test\n\nOR\n\n* Irritable bowel syndrome by Rome IV criteria with a lactulose breath test showing a \"flat line pattern,\" with exhaled gas levels remaining very low (3 parts per million or less) with no spikes\n* Female participants of childbearing age who are sexually active with male partners must agree to use a highly effective method of contraception, such as abstinence, hormonal contraceptive, intrauterine device, or bilateral tubal occlusion\n\nExclusion Criteria:\n\n* Negative SIBO breath testing at baseline\n* Restricted diets (low carbohydrate, Atkins, gluten-free, low FODMAP, or others)\n* Confirmed celiac disease\n* Immunocompromised (chronic steroids, biologics), CD4 less than 400, AIDS not on therapy, neutropenia, acute and chronic leukemia, lymphoma\n* Portal hypertension\n* Chronic liver disease, defined as: ICD-10 known diagnoses of chronic liver disease; OR known or suspected liver cirrhosis, portal hypertension, or chronic hepatitis; OR serum AST and ALT elevation greater than 2 times the upper limit of normal with decreased serum albumin less than 4.0 g\u002FdL within the last 6 months\n* Pregnant or breastfeeding\n* Diagnosis of inflammatory bowel disease\n* Poorly controlled anxiety or depression despite medication\n* Untreated significant anxiety or depression\n* COVID-19 positive\n* Unable to provide informed consent\n* Insulin dependent or poorly controlled diabetes mellitus (HbA1c greater than 7.0%)\n* Connective tissue disease such as lupus or scleroderma\n* Concurrent narcotic use\n* Antibiotic or probiotic use within 30 days","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this clinical trial is to learn if an herbal supplement called Biocidin REMOVE can clear small intestinal bacterial overgrowth (SIBO) in adults with irritable bowel syndrome (IBS). SIBO means there are too many bacteria in the small intestine. It can make IBS symptoms worse.\n\nThis is a small first study, called a pilot study. Its results will help researchers plan larger studies.\n\nThe main questions it aims to answer are:\n\nDoes Biocidin REMOVE clear SIBO? Does it lower IBS symptoms and improve quality of life? Does it change the mix of bacteria in the gut? Researchers will compare Biocidin REMOVE to a placebo. A placebo is a look-alike capsule that contains no active ingredients. Neither the participants nor the research team will know who gets which one. About 40 adults age 18 and older will take part.\n\nParticipants will:\n\nTake capsules by mouth twice a day for about 5 weeks. Participants will start with a low dose and build up to 2 capsules twice a day.\n\nTake a breath test at the start and at the end of treatment. This test checks for SIBO.\n\nCollect a stool sample at home at the start and at the end of treatment. Answer questions about symptoms and quality of life. Report what was eaten during the study. Come back for one check-in about 4 weeks after treatment ends.",[26,27],"Irritable Bowel Syndrome (IBS)","Small Intestinal Bacterial Overgrowth Syndrome (SIBO)",[29,30,31,32,33,34,35,36,37],"SIBO","IBS","Herbal supplement","Antimicrobial herbal therapy","Gut microbiome","Dysbiosis","Rome IV","Hydrogen breath test","Lactulose breath test","NOT_YET_RECRUITING","2026-08-18",{"date":41,"type":42},"2026-08-19","ACTUAL",{"date":44,"type":20},"2026-09-01",{"date":46,"type":20},"2027-08-10",{"name":48,"class":49},"Johns Hopkins University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100625751","phase-4-effect-of-multispecies-probiotic-supplementation-on-the-efficacy-of-rifaximin--therapy-in-patients-with-small-intestinal-bacterial-overgrowth-sibo-a-randomized-placebo-controlled-trial-100625751","NCT07426705","Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial","Effect of Enterococcus Faecium and Bacillus Subtilis-Containing Multispecies Probiotic Supplementation on the Therapeutic Efficacy of Rifaximin α in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Prospective, Randomized, Placebo-controlled Trial","SIBO-Probiotic","Inclusion Criteria:\n\n* Age ≥18 years.\n* Meets Rome IV criteria for irritable bowel syndrome.\n* Written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Lack of cooperation with investigators.\n* Age \\>75 years.\n* Need for modification of gastrointestinal treatment during the study.\n* Use of antibiotics within 4 weeks before screening.\n* Use of probiotics within 7 days before screening.\n* Endoscopic examination within 6 weeks before screening or during the study without investigator approval.\n* History of abdominal surgery.\n* Crohn's disease, ulcerative colitis, microscopic colitis, celiac disease, cystic fibrosis, chronic pancreatitis, liver cirrhosis, or end-stage renal disease.\n* Low FODMAP diet within 4 weeks before screening.\n* Pregnancy or breastfeeding.\n* Lactulose intolerance.","75 Years",{"count":61,"type":20},100,[63],"PHASE4","Small intestinal bacterial overgrowth (SIBO) is a common condition associated with gastrointestinal symptoms such as bloating, abdominal pain, diarrhea, and constipation, particularly in patients with irritable bowel syndrome. Antibiotic therapy with rifaximin is commonly used, but relapse rates remain high.\n\nThis randomized, placebo-controlled clinical trial aims to evaluate whether supplementation with a multispecies probiotic containing Enterococcus faecium and Bacillus subtilis improves the effectiveness of rifaximin therapy in adult patients with SIBO.\n\nParticipants will be randomly assigned to receive either rifaximin plus the probiotic or rifaximin plus placebo. Clinical assessments will include hydrogen breath testing and evaluation of gastrointestinal symptoms using standardized questionnaires at baseline and during follow-up visits.\n\nThe study is being conducted at a single academic medical center in Poland and is sponsored by Państwowy Instytut Medyczny MSWiA. The probiotic and rifaximin are provided by Urgo.\n\nThe results of this study may help determine whether probiotic supplementation can improve treatment outcomes and reduce recurrence of SIBO.",[27,30],[29,30,67],"probiotic","2026-02-16",{"date":70,"type":42},"2026-02-23",{"date":72,"type":20},"2026-02-15",{"date":74,"type":20},"2027-07-15",{"name":76,"class":77},"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","OTHER_GOV",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":50},"100571563","phase-1-herbal-evaluation-of-artemisia-annua-for-small-intestinal-bacterial-overgrowth-100571563","NCT06721884","Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth","Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth: A Phase I\u002FII Triple-Masked, Placebo-Controlled Trial","HERBA-SIBO","Inclusion Criteria:\n\n* Adults 18 years of age or older\n* IBS-SSS score \\>175\n* Meets North American Consensus criteria for H2 SIBO\n* Willing to take Artecinua™ or placebo as a dietary supplement for 5 weeks\n* Willing to have two lactulose breath tests and do the prep diet 24 hours before and fast overnight before the test\n* Willing to have three blood drawstests and fast overnight before the draw\n* Able to speak, read, and understand English\n* Able to provide informed consent\n* For individuals of child-bearing potential, willing to use an intrauterine device or two other concurrent forms of birth control to prevent pregnancy while enrolled\n\nExclusion Criteria:\n\n* Use of antibiotic pharmaceuticals or supplements 14 days before baseline breath test\n* Initiation of change in diet, medication, or supplement regime within 30 days\n* Hospitalization within the past 3 months\n* Women who are breastfeeding, pregnant, or planning pregnancy in the next 4 months\n* Allergies to any of the ingredients in the study products.\n* Individuals with chronic kidney or liver disease, cancer, colorectal disease and\u002For other rare disorders that at the discretion of the PI or Clinical \\*Investigator may impact their safety or confound trial results\n* The use of any high-risk medications with narrow therapeutic indices metabolized by CYP450 enzymes: Warfarin (CYP2C9), Tacrolimus\u002FCyclosporine (CYP3A4), Efavirenz (CYP2B6), and Codeine (CYP2D6).\n* Drugs requiring activation for efficacy: Clopidogrel (CYP2C19), Codeine (CYP2D6), and Tamoxifen (CYP2D6) (citations).\n* GFR: \\\u003C30 mL\u002Fmin\u002F1.73m²\n* Hepatitis from any cause.\n* Excessive alcohol use (\\> seven drinks\u002Fweek in women and \\> fourteen in men).\n* Hepatic (ALT, AST, bilirubin) and renal (creatinine, estimated GFR) parameters outside of normal range at screening.",{"count":87,"type":20},32,[89,23],"PHASE1","Small intestinal bacterial overgrowth (SIBO) can cause symptoms like bloating, stomach pain, and changes in bowel movements, significantly affecting quality of life. Many people with irritable bowel syndrome (IBS) also have SIBO, and there is growing recognition of how important it is to address this condition. Artemisia annua has shown potential in managing SIBO based on early reports and studies suggesting it can fight bacteria like \\*E. coli\\* and \\*Klebsiella\\*, which are linked to a type of SIBO that produces hydrogen gas.\n\nThis study aims to test if Artemisia annua is safe and well-tolerated for adults with hydrogen-type SIBO. Over five weeks, participants will take either 5 grams of dried Artemisia annua leaves or a placebo. Researchers will monitor safety through blood tests, vital signs, and adverse events, and they will assess symptom changes using questionnaires and breath tests.\n\nThe trial will include up to 32 participants from the Portland, Oregon area. Participants will be randomly assigned to treatment groups, and neither they, the researchers, nor the test administrators will know who is receiving the herb or the placebo. Results will be analyzed using standard statistical methods.\n\nThis study addresses the lack of research on herbal treatments for SIBO. If successful, the findings could lead to larger studies and help expand treatment options for people with SIBO.",[27],[93,94,95,29,96],"randomized controlled trial","placebo","artemisia annua","small intestinal bacterial overgrowth","RECRUITING","2025-05-29",{"date":100,"type":42},"2025-06-04",{"date":102,"type":42},"2025-01-01",{"date":104,"type":20},"2026-01",{"name":106,"class":49},"National University of Natural Medicine",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":5},"100570655","urine-metabolites-in-the-diagnosis-of-disease-100570655","NCT06710067","Urine Metabolites in the Diagnosis of Disease","Observational Study of Urine Metabolites in the Diagnosis of Disease","Inclusion Criteria:\n\n* Age ≥ 18 years of age at time of enrollment.\n* Able and willing to provide a one-time urine sample and comply with all study procedures for the study.\n* Able to understand the study procedures, able to provide consent to participate in the study, and willing to authorize release of relevant protected health information by consenting to a HIPAA medical release form.\n\nExclusion Criteria:\n\n* Known to be pregnant.\n* A medical condition which, in the opinion of the Investigator and\u002For Sponsor, should preclude enrollment in the study.",true,{"count":116,"type":20},1250,"OBSERVATIONAL","The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases.\n\nThis research study intends to enroll participants across a range of demographics and GI disease states including colorectal cancer, small intestinal bacterial overgrowth (SIBO), Crohn\\'s disease, and Celiac disease, collect urine samples and clinical data, and use artificial intelligence and machine learning to build disease-specific models which can identify and differentiate a participants' specific GI disease.\n\nThe main questions it aims to answer are:\n\n1. Does the platform identify a disease signal within each disease cohort, compared to normal controls?\n2. How well does the test perform (e.g. sensitivity and specificity\u002Ffalse-positive rate)?",[120,27,121,122],"Colorectal Cancer","Crohn Disease","Celiac Disease","2024-12-11",{"date":125,"type":42},"2024-12-13",{"date":127,"type":42},"2024-10-01",{"date":129,"type":20},"2026-09",{"name":131,"class":132},"Luventix, Inc.","INDUSTRY"]